Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Down 21.6% in January

Alpha Tau Medical Ltd. (NASDAQ:DRTS) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 101,900 shares, a decrease of 21.6% from the January 15th total of 130,000 shares. Based on an average daily volume of 85,200 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the company’s shares are short sold.

Hedge Funds Weigh In On Alpha Tau Medical

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in shares of Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after buying an additional 26,800 shares during the period. Northern Trust Corp grew its position in shares of Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, Levin Capital Strategies L.P. lifted its holdings in Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after purchasing an additional 7,189 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research note on Friday, November 22nd.

Alpha Tau Medical Stock Performance

NASDAQ DRTS traded up $0.08 during trading hours on Monday, hitting $3.14. 31,523 shares of the company traded hands, compared to its average volume of 148,702. The business’s 50-day moving average is $3.39 and its 200-day moving average is $2.70. The stock has a market capitalization of $219.56 million, a price-to-earnings ratio of -7.30 and a beta of 0.83. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $4.39.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.